Fei Zheng

Fei Zheng currently serves as Vice President at China Renaissance 华兴资本 since August 2017, focusing on the Pharmaceutical and Molecular Diagnosis sectors, where responsibilities include industry mapping, project sourcing, and negotiating private placement transactions. Notable completed projects include collaborations with Innocare, CMAB, and I-MAB, while ongoing projects involve TransThera and Genova. Prior to this role, Fei Zheng was a Director at Mefund Capital, overseeing investments in pharmaceutical and medical device sectors, and had significant achievements at HD Biosciences Co., Ltd. as Associate Director, leading numerous projects in drug R&D and target validation. Fei Zheng began the career as a Scientist at Pharmaron, developing protein expression capabilities. Academic qualifications include a Ph.D. in Biochemistry and Molecular Biology from Baylor College of Medicine and a Bachelor's degree in Biology from Peking University.